Man Group plc Buys Shares of 98,839 Elanco Animal Health Incorporated $ELAN

Man Group plc bought a new position in Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 98,839 shares of the company’s stock, valued at approximately $2,432,000.

Other institutional investors also recently made changes to their positions in the company. NewEdge Advisors LLC grew its position in Elanco Animal Health by 133.7% in the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Elanco Animal Health in the 2nd quarter valued at approximately $38,000. Root Financial Partners LLC raised its stake in Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after acquiring an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. acquired a new position in Elanco Animal Health during the 4th quarter worth $41,000. Finally, Bessemer Group Inc. grew its stake in shares of Elanco Animal Health by 33.2% in the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after purchasing an additional 525 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Price Performance

Shares of ELAN opened at $23.91 on Wednesday. The company has a market capitalization of $11.95 billion, a price-to-earnings ratio of -58.32, a P/E/G ratio of 1.43 and a beta of 1.68. Elanco Animal Health Incorporated has a fifty-two week low of $17.11 and a fifty-two week high of $27.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. The business’s 50-day moving average is $24.63 and its 200-day moving average is $23.98.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. During the same period last year, the company posted $0.26 earnings per share. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities research analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Insider Activity at Elanco Animal Health

In other news, CFO Robert M. Vanhimbergen acquired 4,200 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average price of $23.08 per share, for a total transaction of $96,936.00. Following the completion of the acquisition, the chief financial officer owned 137,516 shares of the company’s stock, valued at approximately $3,173,869.28. This represents a 3.15% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Paul Herendeen acquired 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were acquired at an average cost of $23.68 per share, for a total transaction of $236,800.00. Following the transaction, the director owned 111,687 shares of the company’s stock, valued at approximately $2,644,748.16. This represents a 9.83% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders bought 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

ELAN has been the topic of several recent analyst reports. Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, August 20th. UBS Group lifted their price target on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. KeyCorp raised their target price on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Morgan Stanley lifted their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 22nd. Finally, Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Elanco Animal Health has an average rating of “Moderate Buy” and a consensus target price of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.